BioCentury
ARTICLE | Company News

Genmab, IMNX cancer antibody deal

October 8, 2001 7:00 AM UTC

Genmab (CSE:GEN; NMarkt:GE9D) will create a human antibody, to be called HuMax-Lymphoma, against an Immunex (IMNX) lymphoma target, the IL-15 receptor. GEN is responsible for compound development thro...